Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$126.27 USD
+1.85 (1.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$126.27 USD
+1.85 (1.49%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
BDX Stock Declines Despite Launching BD IO Vascular Access System
by Zacks Equity Research
BD announces the BD Intraosseous Vascular Access System to enable quick vascular access for critical care situations.
Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.
ECL Q3 Earnings Surpass Estimates, Revenues Miss, Margins Rise
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its third-quarter sales.
AMIS Stock Surges After RF Ablation Trial Unveils Positive Results
by Zacks Equity Research
Autonomix's RF ablation trial for pancreatic cancer pain shows early success, enabling significant pain relief and opioid elimination in responding patients.
Here's Why You Should Add Veeva Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio raises optimism about the stock. However, escalating costs are concerning.
U.S. Physical Therapy (USPH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
U.S. Physical Therapy (USPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALGN Stock Rise on the Release of Invisalign Smile Architect Software
by Zacks Equity Research
Align Technology unveils Invisalign Smile Architect software with Multiple Treatment Plans for providing customised treatment.
Dentsply Sirona Shares Fall After Suspension of Byte Aligner Products
by Zacks Equity Research
XRAY suspends Byte Aligner sales, citing regulatory review with the FDA, shifting resources to bolster other business areas amid compliance efforts.
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integer Holdings Q3 Earnings Surpass Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR's third-quarter results reflect solid Medical sales and margin expansion amid the divestiture of its Electrochem business.
ALUR Stock Declines Despite Submitting PMA for Allurion Balloon
by Zacks Equity Research
Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.
Talkspace Shares Decline Despite Partnership With Wisdo Health
by Zacks Equity Research
TALK collaborates with Wisdo Health to enhance mental health support for seniors, addressing loneliness and improving access to care for the 65+ community.
LifeMD Shares Decline Even After the Launch of Testosterone Therapy
by Zacks Equity Research
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
ALGN Q3 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Align Technology reports third-quarter 2024 revenue growth. This can be mostly attributed to a robust performance by the Imaging Systems & CAD/CAM Services business segment.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, Encompass Health, Amedisys and Addus HomeCare have been highlighted in this Industry Outlook article.
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
by Zacks Equity Research
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
Reasons to Retain Ecolab Stock in Your Portfolio for Now
by Zacks Equity Research
ECL's focus on cost-efficiency programs raises optimism about the stock.
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
Revvity Shares Decline Despite Launch of Transcribe AI Solution
by Zacks Equity Research
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors.
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
by Zacks Equity Research
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
GEHC Stock Declines Despite the Unveiling of CareIntellect Application
by Zacks Equity Research
GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.
iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
by Zacks Equity Research
IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval
by Zacks Equity Research
BSX receives FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing cardiac mapping and ablation workflows for AF treatment.
Myriad Genetics Shares Fall Despite Partnership With jscreen
by Zacks Equity Research
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch
by Zacks Equity Research
ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.